Chang Nancy T reported grant involving 6,250 shares of Immix Biopharma, Inc. at $0.00 for $0 on May 22, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
6,250Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
428,190Direct
Trade date
May 22, 2026Grant
Filed
May 29, 2026, 5:05 PM ET7-day reporting delay
Accession
0001493152-26-026426Code A · Transaction 93569
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Grant12,500$0.00$0Trade 93570
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 7 calendar days after the transaction date.

IMMX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IMMX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +13%1w ago +10%1d ago −3.7%
Returns since7d −12%30d +11%90d180d1y

Footnotes in full

F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. F2: The Reporting Person is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein. F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.